Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
复制标题
DOI：
10.1016/j.cell.2021.10.011
复制
发表时间：
2021-11-11
期刊：
影响因子：
64.5
通讯作者：
PITCH Consortium
中科院分区：
文献类型：
--
作者：
Payne RP;Longet S;Austin JA;Skelly DT;Dejnirattisai W;Adele S;Meardon N;Faustini S;Al-Taei S;Moore SC;Tipton T;Hering LM;Angyal A;Brown R;Nicols AR;Gillson N;Dobson SL;Amini A;Supasa P;Cross A;Bridges-Webb A;Reyes LS;Linder A;Sandhar G;Kilby JA;Tyerman JK;Altmann T;Hornsby H;Whitham R;Phillips E;Malone T;Hargreaves A;Shields A;Saei A;Foulkes S;Stafford L;Johnson S;Wootton DG;Conlon CP;Jeffery K;Matthews PC;Frater J;Deeks AS;Pollard AJ;Brown A;Rowland-Jones SL;Mongkolsapaya J;Barnes E;Hopkins S;Hall V;Dold C;Duncan CJA;Richter A;Carroll M;Screaton G;de Silva TI;Turtle L;Klenerman P;Dunachie S;PITCH Consortium
英国延长了BNT 162 b2 mRNA疫苗接种间隔，以加速单次接种的人群覆盖率。当时，缺乏试验数据，我们在一项针对英国医护人员的研究中解决了这一问题。第一剂疫苗在数周内诱导了对循环α（B.1.1.7）变体感染的保护。在一项589人的亚组研究中，我们表明，这种单剂量诱导严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）中和抗体（NA B）反应和持续的B和T细胞对刺突蛋白的反应。与传统的3- 4周方案相比，延长给药间隔（6-14周）后的NAb水平更高，伴随着表达白细胞介素-2（IL-2）的CD 4 + T细胞的富集。先前的SARS-CoV-2感染放大并加速了反应。动态细胞和体液应答的这些数据表明，延长给药间隔是一种有效的免疫原性方案。与短方案相比，延长方案后的抗体水平更高延长方案富集表达IL-2的病毒特异性CD 4 + T细胞抗体水平在每次给药后下降，但B和T细胞库保持不变在给予初始剂量后，将第二剂BNT 162 b2 COVID-19疫苗的施用延迟长达6-14周继续提供强有力的保护，并有助于有利的抗体、B细胞和T细胞应答。
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol. BNT162b2 vaccine with an extended interval between doses is highly protective Antibody levels were higher after the extended regimen compared with the short regimen The extended regimen enriches for virus-specific CD4+ T cells expressing IL-2 Antibody levels wane after each dose, but B and T cell pools are maintained After giving a primary dose, delaying administration of a second dose of BNT162b2 COVID-19 vaccine up to 6–14 weeks continues to provide strong protection and contributes to favorable antibody, B cell, and T cell responses.
登录
查看更多内容
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
64.5
作者：
Liu C;Ginn HM;Dejnirattisai W;Supasa P;Wang B;Tuekprakhon A;Nutalai R;Zhou D;Mentzer AJ;Zhao Y;Duyvesteyn HME;López-Camacho C;Slon-Campos J;Walter TS;Skelly D;Johnson SA;Ritter TG;Mason C;Costa Clemens SA;Gomes Naveca F;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Dold C;Temperton N;Dong T;Pollard AJ;Knight JC;Crook D;Lambe T;Clutterbuck E;Bibi S;Flaxman A;Bittaye M;Belij-Rammerstorfer S;Gilbert SC;Malik T;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Baillie V;Serafin N;Ditse Z;Da Silva K;Paterson NG;Williams MA;Hall DR;Madhi S;Nunes MC;Goulder P;Fry EE;Mongkolsapaya J;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
24.8
作者：
Goel RR;Apostolidis SA;Painter MM;Mathew D;Pattekar A;Kuthuru O;Gouma S;Hicks P;Meng W;Rosenfeld AM;Dysinger S;Lundgreen KA;Kuri-Cervantes L;Adamski S;Hicks A;Korte S;Oldridge DA;Baxter AE;Giles JR;Weirick ME;McAllister CM;Dougherty J;Long S;D'Andrea K;Hamilton JT;Betts MR;Luning Prak ET;Bates P;Hensley SE;Greenplate AR;Wherry EJ
通讯作者：
Wherry EJ
影响因子：
17.1
作者：
Esposito I;Cicconi P;D'Alise AM;Brown A;Esposito M;Swadling L;Holst PJ;Bassi MR;Stornaiuolo M;Mori F;Vassilev V;Li W;Donnison T;Gentile C;Turner B;von Delft A;Del Sorbo M;Barra F;Contino AM;Abbate A;Novellino E;Thomsen AR;Christensen JP;Lahm A;Grazioli F;Ammendola V;Siani L;Colloca S;Klenerman P;Nicosia A;Dorrell L;Folgori A;Capone S;Barnes E;PEACHI Consortium
通讯作者：
PEACHI Consortium
影响因子：
64.5
作者：
Moderbacher, Carolyn Rydyznski;Ramirez, Sydney, I;Crotty, Shane
通讯作者：
Crotty, Shane